KRTX Stock Recent News

Karuna Therapeutics (NASDAQ: KRTX ) stock is on the move Monday after releasing results from a Phase 3 clinical trial for KarXT. KarXT is a drug in development by the company to treat adults with schizophrenia.

Karuna Therapeutics said its third study of a schizophrenia treatment succeeded, and KRTX stock surged to a three-month high Monday. The post Karuna Surges To Three-Month High On Another Win In Schizophrenia appeared first on Investor's Business Daily.

Shares of Karuna Therapeutics Inc. KRTX, +1.21% rallied about 14% in premarket trading on Monday after the company said its experimental treatment for adults with schizophrenia met the primary endpoint in a Phase 3 clinical trial. Karuna said the therapy showed an “early and sustained statistically significant reduction of symptoms from Week 2” through the completion of the study, and it plans to submit a new drug application to the Food and Drug Administration by mid-2023.

Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.

As Covid-19 problems settle into recurring problems, other biotechnology targets become more active treatment subjects. The psychiatric and neurological conditions of Karuna's focus are receiving increased investing attention. “Likely” is the keyword in uncertain-future forecasts, where profit-margin capture and stock-price increases are a combination of corporate managerial skills and current market circumstances.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 2:20 p.m. EST. A live webcast of the presentation will be available on the Investor Relations page of Karuna's website at investors.karunatx.

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Bill Meury, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. PST (12:00 p.m. EST).

Karuna Therapeutics, Inc. transitioned a new CEO in yesterday, with the former chief now president of R&D. Questions now arise on Karuna Therapeutics' suitability as a takeover candidate.

Karuna Therapeutics Inc KRTX shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition.

Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.